Trial reportBreast (Edinburgh, Scotland)2026
24-week home-based walking program in the early adjuvant setting in breast cancer patients who receive aromatase inhibitor endocrine therapy: lessons learned from the SAKK 95/17 WISE prospective, randomized, multicenter trial.
Trial report in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Less is more? Questioning the walking dose in the WISE trial.Breast (Edinburgh, Scotland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAromatase inhibitor (AI) induced arthralgia/myalgia (AIA) is a frequent side-effect of adjuvant breast cancer (BC) endocrine therapy. We investigated the effect of a user-friendly activity tracker to accompany a 24-week walking program, from the start of adjuvant AI-therapy, on patient AIA symptom burden and medication adherence.
methods320 early-stage BC patients were included and randomly allocated to the intervention (arm A, n = 158) or control arm (arm B, n = 162). The intervention in arm A was aimed at briskly walking outdoors for 30 min continuously with 100 steps/minute for 5 days a week, versus an unspecified recommendation of physical activity (PA) in arm B. The patients wore an activity tracker with a customized display.
resultsThe intervention compliance in arm A was high, 94% of patients completed the 24-week intervention phase and 68% reached the recommended intervention PA goal. Median daily number of steps was higher in arm A (8542 vs. 7742; p = 0.015). At the end of the intervention phase, activity levels were higher in the intervention group (79.1% vs. 72.8%). These higher values remained unchanged in the follow-up phase at 12 months (79.1% vs. 69.8%) and at 24 months (69.6% vs. 61.1%). Neither the high incidence of AIA during the intervention phase (A:58.2% vs. B:56.2%) nor the reported pain levels differed between the trial arms.
conclusionBC patients are highly motivated to pursue new approaches for health promotion in addition to oncological therapies. Activity trackers with training instructional guidance are useful for maintaining training levels achieved over a longer period of time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.